BodyTel to Launch GlucoTel System in August
JACKSONVILLE, Fla., July 8, 2008 (PRIME NEWSWIRE) — BodyTel Scientific Inc. (OTCBB:BDYT), a developer and manufacturer of wireless telemedical systems, announces today that it has finalized the mass production of all GlucoTel Starter Kit components including GlucoTel Blood Glucose Test Strips and is now preparing the kitting of its first market ready product. After having obtained CE approval on May 28th 2008, BodyTel has already commenced supplies of its innovative blood glucose monitoring and management system GlucoTel to selected partners in CE sensitive countries. GlucoTel will be commercially available in Germany, the Netherlands and the United Arab Emirates (U.A.E.) by August 18th.
Stefan Schraps, CEO of BodyTel, stated, “This is the dawn of a new age for BodyTel. Over the last two years we have been a development stage company, preparing the comprehensive GlucoTel system for regulatory approval and commercial launch. To see the ‘GlucoTel’ blood glucose meter sitting in its starter kit and to see the internet platform ‘BodyTel Center’ as well as the cell phone application ‘BodyTel Mobile’ running so smoothly, fills my heart with pride. From August 18th on, BodyTel will no longer be a development stage company, but an active market player. This is a very exciting time for all of us!”
The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders. GlucoTel electronically measures the blood sugar level and sends it automatically via Bluetooth to the patient’s cell phone. Measured values are automatically transmitted from the cell phone to BodyTel’s online database via mobile internet connection and stored on a long-term basis in the patient’s secured profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or other caregivers, can access the database ‘BodyTel Center’ at www.bodytel.com via the internet at any time using a secure login.
The GlucoTel system is the first system of its kind that can provide real-time monitoring and management through its optional alarm functions. If defined by the caregiver, the BodyTel Center can create an alert message (e.g. via text message or email) that can be sent to caregivers informing them immediately of a potential out-of-range result or other unusual behavior like not performing any test within a predefined time frame. The versatility of the system provides all these tools, but use is completely optional and can be enabled or disabled, based on patient, caregiver or healthcare professional requirements, preventing possible serious complications if action is taken without delay.
BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of measured body values to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel’s products — GlucoTel, PressureTel and WeightTel are each at different stages of development and approval processes. Further information can be found at www.bodytel.com.
Forward Looking Statements
Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,”"plans,”"anticipates,”"believes,”"intends,”"estimates,”"projects,”"aims,”"potential,”"goal,”"objective,”"prospective,” and similar expressions, or that events or conditions “will,”"would,”"may,”"can,”"could” or “should” occur. Forward-looking statements in this news release include: is now preparing the kitting of its first market ready product, GlucoTel will be commercially available in Germany, the Netherlands and the United Arab Emirates (U.A.E.) by August 18th, and that From August 18th on, BodyTel will no longer be a development stage company, but an active market player. It is important to note that the Company’s actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company’s Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company’s periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC’s website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: BodyTel Europe GmbH Michaela Klinger +49 (0)5621 96776 11 firstname.lastname@example.org Chain Relations Torsten Herrmann 06192/96-166-80 email@example.com ZA Consulting Inc. US Investor Relations David Zazoff 212-505-5976